Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Predictors of early relapse in transplant-eligible MM patients

Francesca Gay • 7 Dec 2019
ASH 2019
Multiple Myeloma
FORTE

Francesca Gay, MD, PhD, University of Turin, Turin, Italy, discusses the integrative analysis of baseline prognostic features and achievement of measurable residual disease (MRD) negativity in an attempt to identify the main predictors of early relapse in transplant-eligible multiple myeloma (MM) patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Francesca Gay

1:46
FORTE: MRD by MFC or NGS in myeloma
Francesca Gay • 14 Dec 2020
1:30
MRD: Paving the way for future clinical trials in myeloma
Francesca Gay • 14 Dec 2020
0:45
FORTE: KRd versus KCd treatment for myeloma
Francesca Gay • 14 Dec 2020
1:06
MRD evaluation by MFC and NGS for MM
Francesca Gay • 7 Dec 2019

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals